reSee.it - Related Video Feed

RNA vaccines are short-lived copies of chromosomal recipes that produce selected antigens. Billions of copies are injected into the body, made possible by using plasmids derived from bacteria. These plasmids contain the DNA recipes and can be manipulated to include genes for viral proteins. After bacterial decay, the plasmids are harvested and used as templates to produce RNA copies. The RNA molecules are then packaged into lipid nanoparticles to protect them in the bloodstream. These nanoparticles act as trojan horses, entering cells and releasing their cargo to produce the desired gene product. However, if the recipe comes from an alien book, our immune system will attack the cell.

There is a new mRNA COVID-19 vaccine, but there is no evidence to support its effectiveness or safety in human trials. Additionally, several studies from different countries suggest that these vaccines may actually increase the risk of contracting COVID-19 over time. This is concerning and not a typical outcome.

mRNA vaccines have shown the potential of cell and gene therapy. Two years ago, most people would have refused gene or cell therapy, but the pandemic has increased acceptance of innovative treatments.

The symposium covers the potential safety and threat of “replicating” vaccines, especially LepriCon (leprecon) vaccines, in the context of Covid-19 vaccines and genome‑editing concepts. The speakers present a chain of claims and concerns, some drawing on reports and others presenting theories about how these next‑generation vaccines could behave in humans and populations. Key points and claims presented - Emerging mechanisms and risks: The panel notes that blood vessel inflammation and thrombosis mechanisms are increasingly observed, including in vaccine contexts, with examples from individuals who needed limb amputation and others who developed severe vascular events after vaccination. One case involved a 70‑year‑old man who, after a third dose, developed embolic events necessitating shoulder joint surgery, and another where a 60‑year‑old man developed acute limb ischemia and died; both are presented as suggesting a serious vascular mechanism linked to vaccination, though causal connections are not established. - Replicating/vector vaccines and their concerns:荒川博士 and others discuss LepiCon vaccines as vaccines that replicate inside the body. The concept involves “replicating viral vectors” where the genome can mutate and evolve during replication. The green‑highlighted segment in a slide (the antigen gene) plus a blue/orange segment (replicating gene cassette) is used to describe how LepriCon vaccines are designed to carry viral genes and replicate, with the assertion that replication, mutation, and recombination can occur, potentially generating new variants inside the host. - Differences from conventional vaccines: The discussion contrasts LepriCon vaccines with standard mRNA vaccines. In conventional mRNA vaccines, messenger RNA is delivered and translated into antigen proteins, then degraded; in LepriCon vaccines, replicating RNA/DNA can persist and continue producing antigen, with mutation and recombination possible. The panel emphasizes that LepriCon vaccines use replicating/copying mechanisms and that the genetic material can be copied in ways that differ from natural human biology, potentially creating unpredictable variants. - Central dogma and exceptions: The speakers reference the central dogma (DNA → RNA → protein) but note exceptions in viruses, including RNA viruses that can reverse‑transcribe to DNA (retroviruses) and RNA viruses that replicate RNA directly. They discuss how LepriCon vaccines would rely on replicative processes that do not follow the usual linear flow and why this could complicate predictions about safety and behavior in humans. - Potential for unintended spread and environmental impact: A major concern raised is that self‑replicating vectors could spread beyond the vaccinated individual, via exosomes or other intercellular transport, creating secondary infections or non‑target spread. Exosomes could ferry replicating genetic material, raising fears of new infection chains or “outbreaks” stemming from the vaccine itself, and even suggesting the possibility of vaccination‑induced spread akin to an attenuated or modified pathogen. - Safety signals and immunology concerns: The discussion touches on immune system risks, including immune dysregulation, autoimmune phenomena, and unexpected inflammatory responses. IGG4‑related disease is highlighted as a potential adverse outcome post‑vaccination, with descriptions of glandular and systemic involvement and the idea that high IGG4 levels could have immunosuppressive effects that alter responses to infection or vaccination. The panel notes observed increases in certain immunoglobulin subclasses after multiple LepriCon doses and discusses the possibility of immune tolerance or enhanced immune responses that could be harmful. - Historical and theoretical context: References are made to past epidemics and speculative pandemics caused by misused or dangerous vaccine platforms, drawing on central molecular biology concepts and historical anecdotes about how vaccines can be designed and misused. The discussion frames LepriCon vaccines as a high‑risk platform that could, in theory, generate recombinants, escape mutations, or cause unintended immune and inflammatory consequences. - Clinical and regulatory implications: The speakers call for caution, arguing that more evidence is needed before approving or widespread use of LepriCon vaccines. They emphasize the need for long‑term observation and transparent communication about risks, and criticize the potential for insufficient understanding among healthcare workers and the public. They also urge that any future vaccine development should consider the possibility of genome editing, recombination, and exosome‑mediated spread, and stress the importance of not underestimating possible adverse effects. - Real‑world observations and skepticism about hype: Several speakers underscore that the danger is not merely hypothetical; there are reports of adverse events, including stroke‑like conditions, inflammatory diseases, and immune dysregulation in vaccinated individuals. They stress that the evolution and mutation of replicating vaccines could outpace current surveillance methods, and that “information manipulation” or lack of transparent reporting could mislead the public about risks. - Final reflections and call to action: The concluding messages advocate recognizing the potential failures of messenger RNA vaccines and acknowledging that both conventional and replicating platforms may carry risks. The speakers urge ongoing critical analysis, cautious progression, and robust verification of claims through transparent, independent investigation. They close with thanks to the organizers and a hope that the discussion may contribute to broader public awareness and informed decision‑making. Notable emphasis and unique considerations - The core concern centers on LepriCon vaccines’ replication, mutation, and potential to spread beyond the vaccinated person; exosome transport and genomic/cellular integration are highlighted as mechanisms that could generate new risks not present with non‑replicating vaccines. - The discussion stresses that IGG4 responses could become alarmingly high after certain doses, potentially leading to immunosuppressive effects or autoimmune phenomena, and presents IGG4‑related disease as a potential complication to monitor. - The speakers insist that safety and transparency are paramount, and that misinformation or optimistic narratives about rapid vaccine development could lead to harm if new platforms are adopted without comprehensive evaluation. Overall, the symposium foregrounds cautious scrutiny of replicating vaccine platforms, frames potential biological and regulatory risks, and calls for careful, evidence‑based assessment before broader deployment.

The FDA is considering simplifying COVID vaccinations to one shot annually, similar to the flu shot. Researchers are also developing an mRNA flu vaccine, leveraging technology used in COVID vaccines. Traditional vaccines introduce weakened germs, while mRNA vaccines teach cells to produce proteins that trigger immune responses. This new flu vaccine could be adjusted more easily for different strains during flu season. Although the mRNA flu vaccine may not be superior to traditional ones, it offers an alternative for those who cannot tolerate existing vaccines. Current studies on mRNA vaccines are also exploring options for Lyme disease, rabies, HIV, and Zika, with results for the flu vaccine expected by March.

- The m n r m r n a technology was a radical qualitative leap forward in technology. - The mRNA is a type of vaccine. - The reason it was called a scene was because was a brand name that had a track record of safety, and shoehorning it in that was one of the ways to make sure that people weren't terrified of the technology. - It bears very little resemblance to anything that went before that. - There are different types that they didn't have to contend with the fact that it wasn't the same technology. There are different technologies. - There certainly are. That are different technologies.

The symposium revolves around the science and safety implications of Replicating/Replicon vaccines and broader RNA vaccine platforms, with a sequence of expert presentations and reactions from the panel. -荒川博 presents the central premise that Replicon vaccines (replicating or self-amplifying RNA vaccines) raise unique safety and biosafety concerns beyond traditional mRNA vaccines. He frames the discussion around the idea that these vaccines “increase and mutate” within the host, potentially evolving in ways that could affect humans and populations. He references specific real-world events and case observations, including severe vascular events and tissue damage in some vaccine recipients, as motivation to scrutinize this technology carefully. -荒川 emphasizes that Replicon vaccines differ from conventional mRNA vaccines by embedding replicative machinery so that the RNA self-amplifies inside cells. He explains that, unlike ordinary mRNA vaccines, replication can produce more copies of the RNA and additional viral proteins, potentially leading to unexpected immune and biological consequences. He notes that the Alpha virus replicase used in some designs is designed to enable replication and increased antigen production, but that high mutation and recombination potential could yield variants or new properties. -藤本、藤田（参加者は複数） and others discuss the science of replication in viruses, highlighting the Central Dogma nuances. They describe that normally DNA → RNA → protein is the standard flow, but some viruses (RNA viruses and certain retroviruses) can reverse or bypass parts of this flow (RNA to DNA in retroviruses; RNA to RNA replication in some RNA viruses). This provides a conceptual basis for why replicating vaccines could, in principle, generate abnormal replication dynamics or new variants. -コロナウイルスRNAワクチンの議論では、Repliconの増殖と変異率の高さ、組換えの可能性、体内拡散の可能性を挙げて、「増えると変わる」性質が人の体内でどう影響するかが核心テーマとして挙げられます。アルファウイルス由来のレプリカーゼを使う場合、修復機能が不完全なRNAの増殖過程で、予想外の抗原変異を引き起こすリスクがあるとの指摘が出てきます。 -リスクの具体例として、ウイルスの殻（エンベロープ）とエクソソームを介した分布、自己拡散型ワクチンによる体内の遺伝子素材の取り込み、さらには他の人へ感染・伝播するアウトブレークの可能性、という仮説的懸念が提示されます。レプリコンワクチンは「空の遺伝子を抗原遺伝子に置き換えた陰性空間を持つウイルス」という説明が繰り返され、組換え・遺伝子交換・逆転など、従来のDNA・RNA動態の外に出る事象が起こり得ると議論されます。 -一部のスピーカーは、日本での試験・臨床・規制の動きを取り上げ、FDA/国内基準値を超えるDNA混入、SV40プロモーター混入の報告など、製品レベルでの懸念を指摘します。ケビン・マッカーシー氏の分析紹介では、日本市場で使われているファイザー社のコロナワクチンにDNA混入の痕跡があったこと、SV40プロモーター混入の可能性が指摘され、脂質ナノ粒子を通じた細胞内へのDNA／エクソンの取り込みリスクが懸念事項として挙げられます。これにより、RNAワクチンのフォーマットが終わるのではなく、プラットフォーム自体が拡大・進化する過程で新たなリスクを生む可能性を示唆します。 -IGG4関連疾患の急増とコロナワクチンの関連を例示する報告を紹介。IGG-4抗体が高値となり、多様な臓器炎症を引き起こす病態が観察され、ウイルス感染・ワクチン接種と免疫抑制・過剰免疫の連携が臨床で見られるケースの存在が議論されました。これにより、免疫の過剰反応・異常免疫を招く可能性があるとの懸念が示唆されました。 -ウイルス学・免疫学の専門家は、Repliconワクチンの「増殖・変異・組換えの三拍子」が、長期的・広範な公衆衛生影響をもたらし得る点を強調します。従来のウイルスワクチンの枠組みを超え、自己拡散・他者伝播・遺伝子汚染の可能性を定量的に評価する必要があると主張します。 -議論は、Repliconの潜在的リスクと実利を天秤にかけるもので、現時点で「安全」と断定できないという結論に至る場面が多くありました。実臨床での結果を長期観察で検証し、エビデンスに基づく判断を求める声が複数の speaker から出ました。 -最後に、メディア・一般市民への啓蒙の喚起と、透明性の高い情報提供、そして次世代ワクチン開発の安全性を担保するための厳格な規制・評価の重要性が強調されました。現状の科学的理解には限界があり、今後も公衆衛生への影響を見据えた厳密な検証が不可欠であるとの結論が共有されました。 overall, the event centers on the scientific basis, potential risks, and regulatory considerations of Replicon vaccines, contrasted with traditional mRNA vaccines, with emphasis on mutation, recombination, potential horizontal spread, DNA contamination concerns, immune dysregulation (including IGG4-associated phenomena), and the need for rigorous, transparent evaluation before broad deployment.

The mRNA in vaccines can replicate, including the replication engine, leading to potential spread from person to person. Concerns exist about the inability to stop this replication, with unknown consequences for humanity. The spike protein in these vaccines can be toxic, affecting various tissues. Deployment of this technology in vaccines for humans is already happening, with over 4,000 people injected in Japan.

Self-amplifying RNA (saRNA) is being fast-tracked in the US after approval in Japan and Europe. SaRNA is similar to mRNA but replicates itself like a virus. Concerns are raised about its biodistribution and persistence, suggesting it could act as an STD. A white paper calls for a halt on saRNA vaccine deployment until comprehensive safety studies address contagious risks. It is argued that Moderna and Pfizer shots already shed and act as STDs, transmitting spike protein infections. SaRNA is designed to replicate and remain strong, potentially causing a contagious cancer-like disease. COVID shots may contain cancer-causing viruses like SV40, possibly with SV40 promoters to enhance their effectiveness. mRNA degrades over time, but saRNA is designed to make more of itself. There are ways to detox from mRNA, but not a self-replicator. Ultramethylene Blue is promoted for cell health, available at the Alex Jones store.

We are working on developing new vaccines like TB and HIV using mRNA technology to make them high quality and low cost. Current COVID vaccines are not perfect, so we are working on new versions with longer-lasting protection for diseases like measles and tuberculosis. The mRNA technology also shows promise for cancer vaccines and rapid adaptation to future pandemics. We are even exploring using this technology for animal vaccines.

In 2017, Moderna published a paper on an influenza vaccine using lipid nanoparticles. The study showed that in animals tested, the lipid nanoparticle vaccine spread into the brain, bone marrow, liver, spleen, and the muscle site where it was injected.

A new version of mRNA technology called self-replicating mRNA is emerging. This platform was a competitor to the mRNA platform that was settled upon. There are protests in Japan over self-replicating mRNA vaccines, also called replicons. The original mRNA platform turned people's cells into vaccine factories. To make the mRNA vaccines work, the mRNA transcript was stabilized with pseudouridine. All of the uracils were replaced by something chemically similar to stabilize the molecules. The claim that the mRNA molecules were short-lived was false, as they had been hyper-stabilized. Self-replicating mRNAs borrow machinery from alphavirus. They include the gene for the antigen along with genes for proteins that allow the RNA to copy itself. Instead of stabilizing a single mRNA molecule, the mRNA is allowed to duplicate itself.

Self amplifying mRNA vaccine, which got fast track FDA approval a few months ago for the h five n one influenza. "That's even worse, quote, self replicating. We know Pfizer admits that their COVID shot is self replicating, thus sheds. This is officially sheds." "But now, when these self amplifying mRNA vaccines shed, they are shedding machinery that if you take it into your body, will start producing more mRNA." "There are women who miscarried when they were exposed to the Pfizer vaccine or Moderna vaccine." "Pfizer told their officials that they had to report in the trial if any pregnant woman was exposed to anyone who was vaccinated." So shedding was a problem. So many people, like, didn't take it, but their spouse did. They got sick.

The transcript discusses self-amplifying replicon mRNA injections and asserts that they are being deployed for both humans and animals globally. It states that the UK approved Arcturus Therapeutics’ self-amplifying COVID-19 vaccine for adults over 18, and that the European Union previously approved the same inoculation for adults, placing it in both the EU and the UK. It also claims that Japan approved it in 2023, and that India has approved these replicon injections as well, indicating a global rollout. It highlights that in the United States, the USDA approved the self-amplifying mRNA particle injections for pets, specifically mentioning Merck’s Novavax NXT for dogs and cats, and asserts that this is being injected into pets and that shedding onto human owners across the US is possible. It notes that the FDA has fast-tracked an H5N1 bird flu replicon injection trial, emphasizing concern about these developments. The speaker outlines purported dangers of these replicating genetic materials, including the possibility of shedding from humans to humans or from pets to humans, and the potential for recombination with wild viruses to create chimeric mutants. It emphasizes the claimed approval of Arcturus Therapeutics’ injection “everywhere in the clinical trials” and then provides adverse event statistics: eighty-five percent suffered systemic adverse events, and fifteen percent required medical attention. A Uganda study is cited, claiming that the replicon injections induced severe blood abnormalities in ninety-three percent of recipients, with thrombocytopenia, lymphopenia, and neutropenia reported, implying degraded immune systems and increased risks of internal bleeding in a majority of participants. The Uganda study is also described as showing eighty-five percent experiencing vomiting, high fevers, and feeling absolutely terrible. The speaker concludes with a strong stance against these injections, calling them a “self amplifying assault on humanity” and arguing that they should be pulled off the market and banned for human use. The overall message is a warning about global deployment, potential shedding and recombination risks, significant adverse event rates, and a call to ban self-amplifying mRNA injections for humans. The named entities include Arcturus Therapeutics, Merck, Novavax NXT, and references to regulatory actions in the UK, EU, Japan, India, and the US.

I've been involved in over 50 vaccines, including mRNA vaccines. mRNA is like DNA, giving cells instructions to make proteins. This technology was originally for gene therapy, now used for vaccines. It's a new, experimental technology never used in humans before COVID. Animal studies were skipped for COVID vaccines, a novel approach.

Making mRNA is easy and cheap, which is the key. In the next 5 years, advancements are possible with lipid nanoparticles and their self-assembly. This nano construction surpasses our technological expectations.

Speaker 0: Extremely dangerous self amplifying replicon mRNA injections are currently being deployed for humans and animals across the globe. A few days ago, The UK approved Arcturus Therapeutics self amplifying COVID nineteen injection for adults over 18. Previously, the European Union approved the same Arcturus Therapeutics replicon injection for adults. So it's in The EU. It's in The UK. Japan approved it in 2023. So it's being injected into Japanese citizens as well as India. India has approved these replicon injections as well. And so it is being rolled out across the globe and here in The US is very worrisome. The USDA approved the self amplifying mRNA particle injections for our dogs and cats. This is Novavac NXT by Merck. And so that's actively being injected into our, our pets and probably shedding onto human owners across The United States as well in The US. Our FDA fast tracked an h five n one bird flu replicon injection trial, and we have to remember just how dangerous these are. So not only can they likely shed this replicating genetic material can shed onto other humans or from our pets to humans to the human owners, but they can also recombine with wild viruses and and create these chimeric mutants. But what's most important is this Arcturus Therapeutics injection being approved everywhere in the in the clinical trials for them. Eighty five percent suffered systemic adverse events, fifteen percent required medical attention. And then a recent study in Uganda, it induced severe blood abnormalities in ninety three percent of the recipients. They suffered from thrombocytopenia, lymphopenia, neutropenia. So their immune systems were being degraded, and they were suffering inter increased risks of internal bleeding in a majority of participants. And eighty five percent of them were vomiting, had high fevers, and felt absolutely terrible. So this self amplifying assault on humanity needs to come to an end. We have to pull these off of the market and ban them for human use.

The mRNA platform is effective but has a flaw: it can cause autoimmune disorders by producing foreign proteins in cells. The challenge is to target only specific cells and avoid damage to vital organs. The pandemic allowed the emergency use authorization of mRNA vaccines, bypassing safety measures. However, a large portion of the population has already accepted this technology. To address the issue, a solution could be to replace the spike protein with a different protein that doesn't have flaws. But if the problem lies in any foreign protein transcribed by cells, the immune system may still target vital organs.

The company Biontech in Mainz is working on a new method for producing vaccines. They use mRNA, a natural molecule found in every cell, to stimulate the body to produce the antidote itself. This personalized approach allows them to create a vaccine in just two to four weeks, making it possible to respond quickly to pandemics. The new vaccine is currently undergoing clinical trials, and if successful, it could be approved within five to six years. This breakthrough method could revolutionize the fight against time. However, it remains to be seen which of these new developments will come out on top once all the studies are completed.

The panel discusses replication (replicon) vaccines and their potential dangers, focusing on how they differ from conventional messenger RNA (mRNA) vaccines and what new risks might emerge as this technology develops. Key points and concerns raised - Replicon vaccines concept and fundamental differences - Replicon vaccines use replication-capable genetic material, so the embedded genetic information not only makes antigen proteins but also multiplies inside the cell. They are described as having both constitutive function (the ability to make proteins) and, crucially, the capacity to replicate, which distinguishes them from traditional, non-replicating mRNA vaccines. - It is explained that replication introduces additional mutation and recombination opportunities, because the RNA genome is copied more than once, and the process can produce variants that differ from the original design. - Central dogma exceptions and viral biology - The speakers explain that while the central dogma (DNA → RNA → protein) generally governs biology, some viruses violate this, with RNA viruses that replicate via RNA-dependent replication and even some reverse-transcribing retroviruses that convert RNA to DNA and integrate into genomes. This context is used to frame why replicon vaccines could behave unpredictably. - Potential risks of replication and spread - A core concern is that the replicon approach might allow the vaccine genome to spread beyond the initial target cells, potentially reaching other cells and tissues, or even spreading to other people via exosomes or other means. Exosomes can transport DNA, RNA, and proteins between cells; thus, the replicon genome could in theory be disseminated. - The possibility of homologous or heterologous recombination between replicon genomes and wild-type viruses could yield new variants. The panel emphasizes the difficulty of controlling such recombination in a living system. - Specific material and design considerations - The use of viral components like spike protein genes in replicon vaccines raises concerns about how these proteins might mutate or recombine during replication, potentially altering antigen presentation or safety. - A concern is raised about the lack of repair mechanisms in RNA replication (as opposed to DNA replication), which could make error rates higher and lead to unpredictable changes. - The panel notes that current replicon vaccine designs (including those using alphavirus backbones) inherently carry high mutation and recombination risk, and that the replicating systems may encounter unpredictable evolutionary dynamics inside the human body. - Safety signals and clinical anecdotes - The speakers cite cases of adverse events temporally associated with vaccines, including vascular inflammation and thrombosis, stroke-like events, and myocarditis, to illustrate that immune responses to vaccines can be complex and occasionally severe. They emphasize that such observations do not establish causality, but argue they warrant careful scrutiny. - There are references to cases of acute vascular and neural complications following repeated vaccination, and to broader immune dysregulation phenomena, including IGG4-related disease and immune dysregulation syndromes that can involve multiple organs. - One example concerns a patient who developed sudden limb problems after the third dose, requiring surgery; another describes myocardial involvement after multiple doses and subsequent inflammatory sequelae. - DNA contamination and analytical findings - Kevin McKernan’s analysis of certain Japanese CoronaVac vaccines is cited: both DNA contamination and the presence of SV40 promoter elements were detected in some vaccine lots, with DNA amounts exceeding some regulatory benchmarks in at least one case. The concern is that DNA contamination, or the presence of promoter sequences, could influence integration or expression in unintended ways. - It is noted that vaccines using lipid nanoparticles can potentially deliver nucleic acids into cells; in the presence of exons or promoter sequences, there could be unintended cellular uptake and expression. - Implications for public health and policy - The panel underscores the need for caution, thorough investigation, and long-term observation of any replication-based vaccine platform before broad deployment. There is a call to evaluate risks, monitor long-term outcomes, and consider the possibility that replication-competent constructs could drive unforeseen evolutionary dynamics within hosts or communities. - There is contention about how information is communicated to the public, with particular emphasis on avoiding misinformation while ensuring that scientific uncertainties are transparently discussed. - Broader scientific context and forward-looking stance - The speakers discuss how the field’s approach to gene-based vaccines is evolving rapidly, and they stress that the compatibility of replicon systems with human biology is not yet fully understood. - They frame their discussion as not merely about current vaccines but about the trajectory of vaccine platforms: if replication-based or self-dispersing systems prove too risky or unpredictable, the prudent path might be to favor conventional, non-replicating strategies until safety, efficacy, and containment of unintended spread are more firmly established. Closing and takeaways - The session closes with emphasis on careful evaluation of replicon vaccines, awareness that viral genetics can behave differently in humans than in theory, and a call for continued discussion, independent verification, and transparent communication as the technology develops. - Throughout, speakers acknowledge the complexity of immune responses to vaccines, the potential for unexpected adverse events, and the importance of safeguarding public health while advancing vaccine science.

Pfizer and Moderna vaccines use two processes. The first process involves using PCR to amplify and create DNA for clinical trials. Once approved, they use circular bacterial DNA plasmid to replicate billions of mRNA DNA sample copies. However, this resulted in contaminated vaccines with junk DNA. A study found DNA fragments in Pfizer and Moderna vaccines in Ontario, Canada. Researchers tested 27 mRNA vials from 12 different lots and discovered billions to 100 billions of DNA molecules per dose, exceeding FDA and WHO guidelines by 188 to 509 times. This is a significant amount, far beyond what is acceptable.

Moderna and BioNTech used the first sequence of the SARS CoV-2 genome, published on January 10th, to develop their vaccines. Moderna relied solely on the published data and never had the live virus on their site. This highlights the significance of digitizing biology, as Moderna, a leading company in biology, faced a software problem rather than a biological one.

Speaker asserts that extremely dangerous self-amplifying replicon mRNA injections are currently being deployed for humans and animals worldwide. A few days ago, the UK approved Arcturus Therapeutics’ self-amplifying COVID-19 injection for adults over 18, and previously the European Union approved the same replicon injection for adults, so it is in the EU and the UK. Japan approved it in 2023, and India has approved these replicon injections as well, indicating rollout across the globe. In the United States, it is claimed that the USDA approved the self-amplifying mRNA particle injections for dogs and cats, specifically Novavax NXT by Merck, suggesting active injection into pets and potential shedding onto human owners in the US. The speaker states that the FDA fast-tracked an H5N1 bird flu replicon injection trial, raising concern given the alleged dangers of these products. The speaker emphasizes the potential for shedding of replicating genetic material from humans or from pets to humans, and the possibility that these replicating constructs could recombine with wild viruses to create chimeric mutants. They highlight a high rate of adverse events associated with the Arcturus Therapeutics injection, claiming that eighty-five percent suffered systemic adverse events and fifteen percent required medical attention. A recent study in Uganda is cited, alleged to have induced severe blood abnormalities in ninety-three percent of recipients, including thrombocytopenia, lymphopenia, and neutropenia, with immune systems degraded and increased risks of internal bleeding in a majority of participants. The report also claims that eighty-five percent experienced vomiting and high fevers, and felt absolutely terrible. The speaker concludes that this self-amplifying assault on humanity needs to end, calling for these injections to be pulled from the market and banned for human use.

Nicholas Holcher, an epidemiologist and foundation administrator at the McCullough Foundation, appears on the WiderWake Media Podcast to discuss what he calls harms from the mRNA COVID vaccines and to critique mainstream approaches to the pandemic and public health policy. - Vaccine definitions and mRNA technology - Pre-2000 definition: a vaccine is an injectable or oral product that introduces a killed part of a virus or an inactivated form to the body so that encountering a wild-type version would not infect or would cause a less severe illness. - He asserts that mRNA injections are not vaccines: they are a gene transfer platform using modified messenger RNA with long persistence in the body (via N1-methylpseudouridine), delivered in lipid nanoparticles. He claims these bubbles distribute systemically, including to the brain, heart, bone marrow, and reproductive system, and that they instruct cells to produce a spike protein, effectively turning organs into “toxic spike protein production factories.” He says this leads to autoimmune attack on those tissues and contributes to adverse events, including myocarditis, strokes, immune destruction, and “turbo cancers.” - History and purpose of mRNA in vaccines - According to Holcher, work on this technology existed for decades but animals testing showed high mortality or sterilization in ferrets and mice, preventing approval except under a declared global emergency. He contends the COVID-19 crisis enabled emergency use authorization across Western countries, with ulterior aims to inject the globe with mRNA technology. - Global impact and uptake - He estimates about 70% of the global population received at least one COVID-19 injection (mRNA or viral vector). He notes Eastern countries used non-mRNA platforms (e.g., AstraZeneca/J&J in some places; Sinovac elsewhere) but that uptake in the West was high. - Harms and evidence - Excess deaths: cites a study by Dennis Brancourt et al. estimating around 17 million deaths worldwide as a result of COVID injections (as of September 2023); he claims US deaths could be in the hundreds of thousands to millions. - Turbo cancers: cites multiple studies in 2023 showing increased risk of seven cancer types (colorectal, bladder, breast, thyroid, prostate, etc.) in vaccinated groups; cites a major cancer journal, OncoTarget, reporting hundreds of turbo cancer cases across 27 countries, with Pfizer contributing most cases. Holcher also mentions his own group’s work with Neo7 Bioscience documenting genomic integration of vaccine-derived mRNA in a stage IV bladder cancer patient (31-year-old woman) with a segment of mRNA found in circulating tumor DNA on chromosome 19; another study reported thousands of dysregulated genes in post-vaccine cancers, including p53, KRAS, and BRCA. - Definition of turbo cancer: per Merrick et al., rapid, aggressive tumor progression with sudden onset and early metastasis, often in younger individuals, and resistant to treatment. - Fertility, pregnancy, and autism - Fertility: cites studies suggesting fertility impacts, including Karaman et al. finding depletion of primordial follicles in rats after mRNA vaccination; Manichi et al. reporting 33% lower conception rates in vaccinated women in Denmark; a study indicating a ~20% drop in sperm concentration and motility with no recovery over five months. - Autism: asserts a large body of evidence linking vaccines to neurodevelopmental disorders, citing a 136-study review with 107 studies finding positive associations between vaccines and neurodevelopmental issues, including autism, attributed to toxicity and immune system disruption, particularly in children with high vaccine exposure and reduced detox capacity (CYP450 impairment). - Other topics tied to vaccines and public response - The COVID-19 period and vaccine skepticism: claims the pandemic catalyzed a large anti-vaccine movement because people were compelled to take an experimental gene therapy product. - Sam Altman and gene editing: discusses Altman’s Preventive venture with the aim to reduce heritable diseases via in utero gene editing but warns of the path to designer babies and the potential for harm in early-iteration edits, citing prior CRISPR experiments on human embryos that produced deformed offspring or nonviable results. - AI, workers, and future society: predicts two-tier society with implanted or enhanced individuals and a replacement of human labor by robots and AI systems; discusses military and surveillance ambitions in gene editing and AI augmentation. - Mental health and digital life: references a randomized trial showing that turning off mobile Internet improved depression scores and well-being to an extent comparable to or greater than antidepressants. - World Health Organization (WHO): notes the US has pulled out of the WHO, arguing this is good for the US but potentially harmful for others still in the organization; expresses concerns about the pandemic treaty and ongoing global health governance, including vaccine passport-style surveillance. - FDA and public health policy: acknowledges some shifts (e.g., cutting doses from the childhood schedule) but argues the FDA remains compromised and too aligned with vaccine industry interests; criticizes the removal of a potential black box warning for vaccines and calls for more accountability. - Resources and contact - Holcher invites listeners to follow him on X (Twitter) at @nichulsher and to read their work on focalpoints.com and through McCullough’s network. Note: The transcript presents Holcher’s claims and interpretations about vaccines, turbo cancers, autism, fertility, and policy changes. The summary reproduces these points without endorsement or evaluation.